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The analysis took the perspective of the NHS in England and Wales. Estimates for 
the model input parameters were retrieved from the literature and by consulting 
experts for unpublished data. Accuracy estimates were derived from the 
systematic review which preceded the economic evaluation in this diagnostic 
assessment.  
In the base case, it was assumed that standard troponin testing had perfect 
sensitivity and specificity (reference case) for diagnosing AMI and that only 
patients testing positive on the reference standard (standard troponin), were at 
increased risk for adverse events and would benefit from immediate treatment. 
In a secondary analysis, hs-cTN assays were assigned some additional predictive 
power beyond that of the standard troponin test, in the sense that a proportion 
of patients testing negative on standard troponin but positive on an hs-cTn test 
were assumed to be at increased risk for events, and treated accordingly in case 
of hs-cTn testing but left untreated in case of standard troponin testing. In 
addition, a number of subgroup and sensitivity analyses were performed, as well 










































Results of the PSA are summarized in the table (only base case analysis) and in 
the cost effectiveness acceptability curve (CEAC, see figure). In the base case 
analysis, standard troponin testing was both most effective and most costly. 
Strategies considered cost-effective depending upon ICER thresholds were Abbott 
ARCHITECT hs-cTnI 99th centile, Roche Elecsys hs-cTnT 99th percentile, Abbott 
ARCHITECT hs-cTnI optimal strategy, and the standard troponin test. The Roche 






In the secondary analysis, standard troponin testing was dominated, i.e. it was 
both less effective and more costly than another strategy. Sensitivity analyses 
showed main drivers to be the difference in outcomes between treated and 
untreated patients, and treatment costs for patients testing false-positive. As for 
subgroups, hs-cTn testing is more cost-effective in younger age, pre-existing 
coronary artery disease, and symptom onset <3hrs ago. No testing is only cost-


















The economic model does not provide strong evidence to prefer one hs-cTn 
testing strategy over another. Results do, however, indicate that hs-cTn testing in 
general may be cost-effective compared to standard troponin testing given that 
hs-cTn testing leads to cost-saving at a QALY loss. Hs-cTn testing dominates 
standard troponin if one assumes that hs-cTn testing detects some patients who 
require treatment despite their testing negative with standard troponin, as shown 
in the secondary analysis. The main issue, if implementation of an hs-cTn testing 
strategy is considered, is the balance between the likely reduction in cost and the 




















People presenting at the Emergency Department (ED) with acute chest pain 
suspected to be of cardiac origin, but with an electrocardiogram negative for a 
persistent ST-Segment elevation, may be suffering from a Non-ST Segment 
Elevation Myocardial Infarction (NSTEMI). Further diagnostic workup of these 
patients is performed by testing for cardiac biomarkers (preferably troponin) to 
assess cardiac muscle damage. Since troponin sensitivity is suboptimal in the 
initial hours after symptom onset, clinical guidelines recommend to perform 
repeat troponin testing, at respectively 10-12 hours after symptom onset and 6-9 
hours after initial assessment. The waiting time for the repeat testing is 
burdensome for patients, and it requires a hospital admission which incurs 
additional costs.  
 
High-sensitivity troponin (hs-cTn) assays have shown promise in that they have 
better sensitivity at presentation and could rule out NSTEMI within the four hour 
NHS emergency department target. However, hs-cTn assays do not have perfect 
accuracy either and using them for decision making will inevitably also lead to 
discharging patients that should have been treated. At present, it is not clear 
whether the benefits of an early rule-out strategy outweigh the negative 
consequences. The aim of this study, which was performed within a NICE 
diagnostic assessment (NIHR HTA Programme project no. 13/51/01), was to 
assess the cost-effectiveness of high sensitivity troponin assays for the 
management of adults presenting with acute chest pain, in particular for the 
early rule-out of AMI. 
 
 
We considered the long-term costs and quality adjusted life years (QALYs) 
associated with different troponin testing methods, to diagnose or rule-out 
NSTEMI, for patients presenting at the ED with suspected non-ST-segment-
elevation acute coronary syndrome (NSTE-ACS). The model consisted of a 
decision tree and a Markov model. The decision tree was used to model the 30 
day outcomes after presentation, based on test results and the accompanying 
treatment decision. The outcome of the short term model defined the mix of 
health states in which the cohort would enter the long term model. The long-
term consequences in terms of costs and QALYs were estimated using a Markov 
cohort model (see figure) with a lifetime time horizon (60 years).   
 
The following strategies were included in the analysis:  
•Standard troponin at presentation and at 10-12 hours (reference standard) 
•Roche Elecsys hs-cTnT 99th centile threshold at presentation  
•Roche Elecsys hs-cTnT optimal strategy LoB threshold at presentation followed by 99th centile 
threshold peak within three hours and/or Δ20% (compared to presentation test) at 1-3 hours 
•Abbott ARCHITECT hs-cTnI 99th centile threshold at presentation  
•Abbott ARCHITECT hs-cTnI optimal strategy LoD threshold at presentation, followed by 99th 
centile threshold at three hours 
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Wilingness to pay per QALY (£/QALY)
Cost Effectiveness Acceptability Curve
Standard troponin base case Roche Elecsys hs-cTnT - 99th centile base case
Roche Elecsys hs-cTnT optimal base case Abbott ARCHITECT hs-cTnI - 99th centile base case
Abbott ARCHITECT hs-cTnI optimal base case Standard troponin secondary
Roche Elecsys hs-cTnT - 99th centile secondary Roche Elecsys hs-cTnT optimal secondary
Abbott ARCHITECT hs-cTnI - 99th centile secondary Abbott ARCHITECT hs-cTnI optimal secondary
ACS = Acute Coronary Syndrome 
UA = Unstable Angina 
Strategy   Costs (95% CI) QALYs (95% CI)  Compared to delta C delta Q ICER 
No testing £1675 (£1233 - £2182) 11.637 (10.228 - 13.103)         
Abbott 99th centile £2253 (£1702 - £2877) 11.712 (10.312 - 13.157)      
Roche 99th centile £2296 (£1731 - £2936) 11.718 (10.319 - 13.165) Abbott 99th centile £42 0,006 £6.625 
Roche strategy £2422 (£1846 - £3077) 11.723 (10.326 - 13.171) Roche 99th centile £126 0,005 extendedly dominated 
Abbott strategy £2491 (£1908 - £3148) 11.728 (10.328 - 13.177) Roche 99th centile £195 0,010 £19.921 
Standard troponin £2697 (£2113 - £3359) 11.73 (10.334 - 13.179) Abbott strategy £206 0,002 £90.725 
 
